SAN DIEGO, Calif.--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, celebrates two years of progress in pioneering a novel non-profit approach to providing personalized experimental antisense ...
SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, today announced the publication of an article in Nature Biotechnology (Crooke, S.T., et al. Nature Biotechnology advanced online ...
Opinion
15dOpinion
n-Lorem Publishes Commentary Offering Insight into Potential Commercialization Strategies for Nano-rare Medicines
The commentary titled 'Establishing a Commercial Solution for Extremely Rare Genetic Diseases' was published in Nature Biotechnology Commentary coincides with draft guidance from the FDA outlining a ...
SAN DIEGO, Jan. 26, 2021 /PRNewswire/ -- n-Lorem Foundation, the first and only nonprofit organization whose mission is to create experimental antisense oligonucleotide (ASO) treatments for patients ...
SAN DIEGO and GENEVA, Jan. 12, 2026 /PRNewswire/ -- The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to n-Lorem's antisense ...
Foundation’s collaboration with premier rare disease company strengthens efforts to reach more patients in need n-Lorem Foundation is the first and only foundation with a mission to provide ...
Retirement typically means more time for traveling, hobbies, and relaxation. For Stan Crooke, MD, PhD, it means something very different. Crooke, the founder and executive chairman of Ionis ...
n-Lorem, a nonprofit foundation, and GondolaBio, a clinical-stage biotechnology company founded in 2024 and dedicated to developing novel medicines for patients living with genetic diseases, today ...
CARLSBAD, Calif., Dec. 17, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder ...
The MarketWatch News Department was not involved in the creation of this content. n-Lorem Foundation Has Treated 15 Nano-rare Patients and Expects to Treat More Than 25 Nano-rare Patients by Year End ...
Commentary coincides with draft guidance from the FDA outlining a framework to accelerate development of treatments for ultra-rare diseases Traditionally, nano-rare (affecting 30 people or fewer ...
n-Lorem, a nonprofit foundation, announced today that its Founder, Chairman and CEO, Stanley T. Crooke, M.D., Ph.D., and Andrew W. Lo, Ph.D., Professor at the MIT Sloan School of Management and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results